To see the other types of publications on this topic, follow the link: National Foundation for Cancer Research.
Journal articles on the topic 'National Foundation for Cancer Research'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'National Foundation for Cancer Research.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Salisbury, Franklin. "National Foundation for Cancer Research." Neoplasia 3, no. 1 (January 1, 2000): 88–90. http://dx.doi.org/10.1038/sj.neo.7900130.
Full text
2
Donovan, Claire, Linda Butler, Alison J. Butt, Teresa H. Jones, and Stephen R. Hanney. "Evaluation of the impact of National Breast Cancer Foundation‐funded research." Medical Journal of Australia 200, no. 4 (March 2014): 214–18. http://dx.doi.org/10.5694/mja13.10798.
Full text
3
Hong, Wei, Cui Li, LiPing Zhang, YanYing Xu, Jun Zhang, Hai Hu, and ErDan Dong. "Achievements in cancer research supported by National Natural Science Foundation of China." Chinese Science Bulletin 58, no. 1 (January 2013): 39–43. http://dx.doi.org/10.1007/s11434-012-5633-x.
Full text
4
Burgess, Mark. "Mustard gas, electrodes and PARP: Serendipity in cancer research." Biochemist 31, no. 6 (December 1, 2009): 14–15. http://dx.doi.org/10.1042/bio03106014.
Full textAbstract:
Herbie Newell is Professor of Cancer Therapeutics, Northern Institute of Cancer Research, Newcastle upon Tyne. He left school at the age of 16 and went to work as a technician in the Marie Curie Memorial Foundation Research Laboratory, gaining Ordinary National Certificate (ONC) and Higher National Certificate (HNC) in Applied Biology on day release. He gained his PhD after 5 years as a part time student. At present he manages the research and careers of people involved in drug discovery at the University of Newcastle, and has worked for many years with Cancer Research UK in promoting bench-to-bedside research for patient benefit.
5
Crea, Francesco. "Neuroendocrine prostate cancer: long noncoding RNAs to treat an incurable cancer – an interview with Dr Francesco Crea." Epigenomics 11, no. 13 (October 2019): 1461–62. http://dx.doi.org/10.2217/epi-2019-0236.
Full textAbstract:
Francesco Crea speaks to Lucy Chard, Commissioning Editor. Dr Crea’s lab studies the role of epigenetic factors and noncoding RNA in cancer initiation and progression. While working at the National Cancer Institute (USA), Dr Crea has demonstrated that polycomb-targeting drugs eradicate prostate cancer stem cells. While working at the BC Cancer Agency (Canada), Dr Crea discovered and patented PCAT18, a long noncoding RNA involved in prostate cancer metastasis. Dr Crea has received awards from the American Society of Clinical Oncology, from the Prostate Cancer Program and from Prostate Cancer Foundation BC. He is also an Editorial Board member for Epigenomics. His team is currently working on developing new biomarkers and therapeutic targets for incurable prostate and breast cancers.
6
Ayanian, John Z., and Paul B. Jacobsen. "Enhancing Research on Cancer Survivors." Journal of Clinical Oncology 24, no. 32 (November 10, 2006): 5149–53. http://dx.doi.org/10.1200/jco.2006.06.7207.
Full textAbstract:
The United States devotes substantial resources to understanding the etiologies of cancer and improving treatments, but much less research has focused on the needs of cancer survivors after they have completed active treatment. This article augments findings from the Institute of Medicine about cancer survivorship research and ways to enhance quality of life and quality of care. Studies of cancer survivors should focus on mechanisms and risk factors for impaired quality of life and evaluate interventions to improve this domain. Research to improve quality of care should concentrate on survivorship care plans, surveillance tests, respective roles of primary and specialty care, and performance measures related to survivorship care. Opportunities to expand research on cancer survivors include clinical trials, large cohort studies, cancer registries, and national surveys. Research to understand the needs of cancer survivors will provide a foundation for effective programs to meet these needs.
7
Hayes-Lattin, Brandon, Beth Mathews-Bradshaw, and Stuart Siegel. "Adolescent and Young Adult Oncology Training for Health Professionals: A Position Statement." Journal of Clinical Oncology 28, no. 32 (November 10, 2010): 4858–61. http://dx.doi.org/10.1200/jco.2010.30.5508.
Full textAbstract:
We outline here the essential elements of training for health care professionals who work with adolescent and young adult (AYA) patients with cancer. Research is emerging that a number of cancers manifest themselves differently in the AYA population, both in terms of biology and treatment response. In addition, there are a number of issues uniquely experienced by the AYA population that are critical for health care professionals working within AYA oncology (AYAO) to understand. The LIVESTRONG Young Adult Alliance, a Lance Armstrong Foundation program and a result of the Adolescent and Young Adult Oncology Progress Review Group cosponsored by the Lance Armstrong Foundation and the National Cancer Institute, assembled a group of experts representing relevant medical, psychosocial, and advocacy disciplines to create a blueprint for the training and development of health care professionals caring for AYA patients with cancer. The Alliance recommends that all health care professionals working in AYAO receive training that provides expertise in the following three critical areas: AYA-specific medical knowledge; care delivery specific to AYAs relative to pediatric and older adult populations; and competency in application and delivery of AYA-specific practical knowledge. These three areas should form the foundation for curricula and programs designed to train health care professionals caring for AYAO patients.
8
Hopper, John L., Carmel Apicella, and Alison J. Butt. "Register4: an Australian web‐enabled resource created by the National Breast Cancer Foundation to facilitate and accelerate cancer research." Medical Journal of Australia 200, no. 8 (May 2014): 460. http://dx.doi.org/10.5694/mja14.00164.
Full text
9
Kim, Young Ae, Ye-Rin Lee, Jeongjoo Park, In-Hwan Oh, Hoseob Kim, Seok-Jun Yoon, and Keeho Park. "Socioeconomic Burden of Cancer in Korea from 2011 to 2015." Cancer Research and Treatment 52, no. 3 (July 15, 2020): 896–906. http://dx.doi.org/10.4143/crt.2019.398.
Full textAbstract:
PurposeThough the socioeconomic burden of cancer on patients is increasing in South Korea, there is little research regarding the type of cancer that incurs the highest costs. This study analyzed the socioeconomic burden on cancer patients from 2011 to 2015 according to sex and age.Materials and MethodsA prevalence-based approach was applied utilizing claim data of the National Health Insurance Service in Korea to estimate the socioeconomic burden of cancer on patients. Patients who received treatment for cancer from 2011 to 2015 were the study subjects. The total socioeconomic burden of their disease and treatment was divided into direct and indirect costs.ResultsThere was an increase of 50.7% for 5 years, from 821,525 to 1,237,739 cancer patients. The cancer costs for men and women increased $8,268.4 million to $9,469.7 million and $3,626.5 million to $4,475.6 million, respectively. Furthermore, the 50-59-year-old age group accounted for a large portion of the total disease cost. Liver, lung, stomach, and colorectal cancers created the heaviest economic burdens on patients.ConclusionOverall, this study indicates new policies for cancer prevention, early detection, and postcancer treatment management are necessary to help limit the costs associatedwith cancer, especially in the elderly, and provides a foundation for establishing cancer-related health care policies, particularly by defining those cancers with heavier disease burdens.
10
Victorian, Brande. "International Atomic Energy Agency & National Foundation for Cancer Research Join in Initiative to Improve Cancer Care in Developing Countries." Oncology Times 29, no. 21 (November 2007): 29. http://dx.doi.org/10.1097/01.cot.0000300442.91461.90.
Full text
11
Williams, P. Mickey, Thomas Forbes, Steven P. Lund, Kenneth D. Cole, Hua-Jun He, Chris Karlovich, Cloud P. Paweletz, et al. "Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health." JCO Precision Oncology, no. 5 (May 2021): 910–20. http://dx.doi.org/10.1200/po.20.00528.
Full textAbstract:
PURPOSE We report the results from a Foundation for the National Institutes of Health Biomarkers Consortium project to address the absence of well-validated quality control materials (QCMs) for circulating tumor DNA (ctDNA) testing. This absence is considered a cause of variance and inconsistencies in translating ctDNA results into clinical actions. METHODS In this phase I study, QCMs with 14 clinically relevant mutations representing single nucleotide variants, insertions or deletions (indels), translocations, and copy number variants were sourced from three commercial manufacturers with variant allele frequencies (VAFs) of 5%, 2.5%, 1%, 0.1%, and 0%. Four laboratories tested samples in quadruplicate using two allele-specific droplet digital polymerase chain reaction and three (amplicon and hybrid capture) next-generation sequencing (NGS) panels. RESULTS The two droplet digital polymerase chain reaction assays reported VAF values very close to the manufacturers’ claimed concentrations for all QCMs. NGS assays reported most single nucleotide variants and indels, but not translocations, close to the expected VAF values. Notably, two NGS assays reported lower VAF than expected for all translocations in all QCM mixtures, possibly related to technical challenges detecting these variants. The ability to call ERBB2 copy number amplifications varied across assays. All three QCMs provided valuable insight into assay precision. Each assay across all variant types demonstrated dropouts at 0.1%, suggesting that the QCM can serve for testing of an assay’s limit of detection with confidence claims for specific variants. CONCLUSION These results support the utility of the QCM in testing ctDNA assay analytical performance. However, unique designs and manufacturing methods for the QCM, and variations in a laboratory’s testing configuration, may require testing of multiple QCMs to find the best reagents for accurate result interpretation.
12
Pabbathi, Smitha, and Mary Ann Morgan. "Survivorship model of care at a large National Cancer Institute." Journal of Clinical Oncology 34, no. 3_suppl (January 20, 2016): 37. http://dx.doi.org/10.1200/jco.2016.34.3_suppl.37.
Full textAbstract:
37 Background: There is a lack of existing evidence on survivorship care models and their advantages and disadvantages when it comes to improving health outcomes. We describe the evolution of a Survivorship Care model at a large NCI designated Cancer Institute. Our model is closest to ASCO’s description of General Survivorship Clinic/Shared Care. The Clinic is led by a full time nurse practitioner and two part time internists. Initial start-up expenses were provided by Foundation funds Methods: Aggregate data was requested from Information Shared Services. Data was extracted from both Billing from Transmed-HRI and the Cancer Registry from the time period of May 2011 to August 2015 to identify patients who have been followed in the long-term Survivorship clinic. Results: Our program initially focused on breast and prostate cancer populations based on SEER data of cancer survivors and risk-stratification. Twelve other cancer types are now referred resulting in steady growth. A review of our patient population revealed 924 unique patients of which 619 were female and 305 male. Fifty-nine patients fell in the age range 20-44, 445 in the age range 45-65, and 420 > 65 age. Over fifty percent of our patients are from the Breast Program; the next largest population is Genito-Urinary and third largest group is Digestive. The patients racially identified as white are 89%, 6.3% black, 2.7% as other, 2% unknown. This is consistent with the center population. Eighty patients had recurrences or new primaries. Conclusions: The number of referrals has grown every year and the majority of patients continue to be followed annually. Patients do not feel lost in transition because we have a team based approach as the parent program exists within the institution. Our model not only allows our oncologists to focus on new patients and those with recurrent or metastatic disease but it can help bridge survivorship care from the oncologist to primary care physicians in the community. This type of clinic will also facilitate evaluation and treatment of late effects such as anthracyclines and pelvic radiation across diseases for management of symptoms.
13
Ribeiro, Raul C., Federico Antillon, Francisco Pedrosa, and Ching-Hon Pui. "Global Pediatric Oncology: Lessons From Partnerships Between High-Income Countries and Low- to Mid-Income Countries." Journal of Clinical Oncology 34, no. 1 (January 2016): 53–61. http://dx.doi.org/10.1200/jco.2015.61.9148.
Full textAbstract:
Partnerships between medical institutions in high-income countries (HICs) and low- to mid-income countries (LMICs) have succeeded in initiating and expanding pediatric cancer control efforts. The long-term goal is consistently a sustainable national pediatric cancer program. Here, we review the elements required for successful implementation, development, and long-term sustainability of pediatric cancer programs in LMICs that first arise as partnerships with institutions in HICs. Although plans must be adapted to each country's resources, certain components are unfailingly necessary. First, an essential step is provision of treatment regardless of ability to pay. Second, financial support for program development and long-term sustainability must be sought from sources both international and local, public and private. A local leader, typically a well-trained pediatric oncologist who devotes full-time effort to the project, should direct medical care and collaborate with hospital, governmental, and community leadership and international agencies. Third, nurses must be trained in pediatric cancer care and allowed to practice this specialty full-time. It is also essential to develop a grassroots organization, such as a foundation, dedicated solely to pediatric oncology. Its members must be trained and educated to provide pediatric cancer advocacy, fundraising, and (in concert with government) program sustainability. Finally, a project mentor in the HIC is crucial and should explore the possibility of collaborative research in the LMIC, which may offer significant opportunities. Relationships between the partnership's leaders and influential individuals in the community, hospital, grassroots foundation, and government will lay the foundation for productive collaboration and a sustainable pediatric oncology program.
14
Kahn, Justine M., Nmazuo W. Ozuah, Kieron Dunleavy, Tara O. Henderson, Kara Kelly, and Ann LaCasce. "Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes." Blood Advances 1, no. 22 (October 10, 2017): 1945–58. http://dx.doi.org/10.1182/bloodadvances.2017008748.
Full textAbstract:
Abstract Lymphomas are responsible for approximately 20% to 25% of annual cancer diagnoses in the adolescent and young adult (AYA) population. In 2006, the National Cancer Institute and the Lance Armstrong Foundation developed a joint Adolescent and Young Adult Oncology Progress Review Group (AYAO-PRG) to formally address the unique cancer burden of patients age 15 to 39 years. As part of their recommendations, the AYAO-PRG identified 5 imperatives for improving outcomes of AYAs with cancer. Broadly, the recommended areas of focus included research, awareness and education, investigational infrastructure, care delivery, and advocacy. In response to the challenges highlighted by the AYAO-PRG, the Lymphoma Research Foundation held the first AYA Lymphoma Research Foundation Symposium on 2 October 2015. At this symposium, clinicians and basic scientists from both pediatric and adult disciplines gave presentations describing the state of the science and proposed a collaborative research agenda built on the imperatives proposed by the AYAO-PRG. The following review presents an in-depth discussion of lymphoma management across pediatric and adult oncologic disciplines, focusing on Hodgkin lymphoma, mature B-cell lymphomas, and anaplastic large cell lymphoma.
15
Abernethy, Amy P., Lynn M. Etheredge, Patricia A. Ganz, Paul Wallace, Robert R. German, Chalapathy Neti, Peter B. Bach, and Sharon B. Murphy. "Rapid-Learning System for Cancer Care." Journal of Clinical Oncology 28, no. 27 (September 20, 2010): 4268–74. http://dx.doi.org/10.1200/jco.2010.28.5478.
Full textAbstract:
Compelling public interest is propelling national efforts to advance the evidence base for cancer treatment and control measures and to transform the way in which evidence is aggregated and applied. Substantial investments in health information technology, comparative effectiveness research, health care quality and value, and personalized medicine support these efforts and have resulted in considerable progress to date. An emerging initiative, and one that integrates these converging approaches to improving health care, is “rapid-learning health care.” In this framework, routinely collected real-time clinical data drive the process of scientific discovery, which becomes a natural outgrowth of patient care. To better understand the state of the rapid-learning health care model and its potential implications for oncology, the National Cancer Policy Forum of the Institute of Medicine held a workshop entitled “A Foundation for Evidence-Driven Practice: A Rapid-Learning System for Cancer Care” in October 2009. Participants examined the elements of a rapid-learning system for cancer, including registries and databases, emerging information technology, patient-centered and -driven clinical decision support, patient engagement, culture change, clinical practice guidelines, point-of-care needs in clinical oncology, and federal policy issues and implications. This Special Article reviews the activities of the workshop and sets the stage to move from vision to action.
16
Lee, D., and T. Altar. "The Biomarkers Consortium: A public-private partnership of the Foundation for NIH." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 14142. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.14142.
Full textAbstract:
14142 Background: In October 2006, the Foundation for the National Institutes of Health (FNIH) announced the launch of a major public-private biomedical research partnership, The Biomarkers Consortium, to search for and validate new biological markers-biomarkers- to accelerate dramatically the delivery of successful new technologies, medicines, and therapies for prevention, early detection, diagnosis, and treatment of disease. The Foundation for NIH is managing The Biomarkers Consortium under direction of the consortium executive committee, with guidance from leading scientists within and outside the member organizations, plus input from a public representative and private industry and non-profit funding partners. FNIH, CMS, FDA, NIH, and the pharmaceutical, biotechnology, diagnostics, and medical device industries recognize the critical need for a coordinated cross-sector partnership effort to more rapidly identify and qualify biomarkers to support basic and translational research, guide clinical practice and, ultimately, support the development of safe and effective medicines and treatments for a wide range of diseases. The Biomarkers Consortium will harmonize approaches to identifying viable biomarkers, verifying their individual value, and formalizing their use in research and regulatory approval. Information and results from consortium projects will be used broadly by researchers to promote the appropriate use of biomarkers to improve the public health worldwide. Methods: N/A Results: Promising project concepts that have been approved in principle for further development by The Biomarkers Consortium include the Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) Lung Cancer and Non-Hodgkin’s Lymphoma Projects and projects in metabolic disorders and neuroscience. Steering Committees in cancer, metabolic disorders, and neuroscience have been created to evaluate and develop project concepts approved for further development. Conclusions: The Biomarkers Consortium is an important avenue to facilitate the search and validation of a variety of biomarkers projects. No significant financial relationships to disclose.
17
Munigala, Satish, Eileen Mary O'Reilly, Matthew Alsante, Jane Holt, Andrew H. Ko, and Andres Gelrud. "Improving outcomes and shared decisions in pancreatic cancer using animated pancreas patient (APP) visual formats of learning: A National Pancreas Foundation (NPF) patient education initiative." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e16242-e16242. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e16242.
Full textAbstract:
e16242 Background: Pancreatic cancer (PC) outcomes continue to be dismal in the United States (US) and worldwide. Efforts are focused on early diagnosis, treatment, and prevention. However, knowledge translation in PC and effective resources that address patient-provider collaborative decisions are limited and barriers to health literacy continue to impede patient understanding. Evidence increasingly supports the need for informative education for patients to facilitate shared decisions in critical cancer interventions. We evaluated the National Pancreas Foundation’s APP, a visual approach to learning, to determine how shared-decision making and patient barriers to health literacy can be improved, leading to better patient-provider decisions and outcomes. Methods: Using visual formats of learning (animations, videos, and slide shows), we monitored APP website and YouTube metrics from September 2013 to February 2021. We evaluated learner activity, number of views with highest retention in US and globally. Results: APP gathered 4,551,079 views (489,091 views on the APP website and 4,061,988 views on YouTube) from over 100 countries. The majority of viewers (60%) were from the US with 54% being patients, 17% family/caregivers, 16% healthcare providers and 13% other. The animations "Understanding Clinical Trials", "Pancreatic Cancer: Treatment and Outcomes", “Pancreatic Cancer: Signs, Symptoms and Risk Factors", and "Pancreatic Cancer: Pathophysiology, Diagnosis and Staging" had 1,372; 4,643; 8,819 and 4,359 views respectively on the website and 180,845; 77,942; 56,151 and 23,112 views respectively on YouTube. Top expert videos viewed most were "What are the different stages of pancreatic cancer?", "What are the symptoms of pancreatic cancer?", “What is a “Placebo” in a clinical trial and is it always used?”, and “What should I expect following surgery to remove a malignant pancreatic cancer tumor?" with 488; 1,558; 76 and 239 views respectively on the website and 14,869; 10,917; 5,206 and 3,624 views respectively on YouTube. Conclusions: Our study suggests visual formats of education are effective in communicating complex health information to persons with poor health literacy. Pancreatic cancer education based on visual formats have vast potential to provide effective learning for patients. Continued efforts should be made to provide resources for patient-provider shared decisions and address patient health literacy barriers for best health outcomes.
18
Abderrahman, Balkees, and V. Craig Jordan. "Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women’s Health." Endocrinology 159, no. 8 (June 19, 2018): 2980–90. http://dx.doi.org/10.1210/en.2018-00263.
Full textAbstract:
AbstractThe signing of the National Cancer Act in 1971 was designed to take laboratory discoveries rapidly from the bench to the bedside. A “war on cancer” had been declared. Combination cytotoxic chemotherapy was predicted to cure all cancers, based on the stunning success in treating childhood leukemia. Breast cancer treatments were primitive; radical mastectomy and radiation were standard of care for disease that had not spread. Ablative endocrine surgery (oophorectomy, hypophysectomy, and adrenalectomy) was a palliative last option for metastatic breast cancer. However, only 30% responded, surviving for only 1 or 2 years: every patient soon died. The discovery of the estrogen receptor (ER) and translation to breast cancer treatment triggered a revolution in women’s health. Two important but interconnected events occurred in 1972 at the Worcester Foundation for Experimental Biology (WFEB) that would exploit the breast tumor ER as the first target to save lives and prevent breast cancer development. Two new groups of medicines—selective ER modulators (SERMs) and aromatase inhibitors (AIs)—would continue the momentum of research at the WFEB to improve women’s health. Here, we recount the important progress made in women’s health based on knowledge of the endocrinology of breast cancer. We propose future opportunities in SERM therapeutics to “refresh” the current standards of care for breast cancer treatment. The opportunity is based on emerging knowledge about acquired resistance to long-term adjuvant AI therapy used to treat breast cancer.
19
Post, Kathryn Elizabeth. "Understanding patient engagement in breast cancer survivorship care: A national web-based survey." Journal of Clinical Oncology 37, no. 27_suppl (September 20, 2019): 223. http://dx.doi.org/10.1200/jco.2019.37.27_suppl.223.
Full textAbstract:
223 Background: Little is known about patient engagement (PE) into survivorship care (SC). Information is needed to further explore PE into SC, what factors may contribute to it and which patients are more likely to engage in SC and thus be better equipped to self-manage during survivorship. Purpose: The purpose of this study was to explore how demographic/personal factors and survivorship variables are related to and may contribute to PE in early stage breast cancer survivors. Methods: A cross-sectional, web-based self-report national survey was conducted using measures assessing personal/demographic factors, survivorship variables: health-related quality of life (HRQOL), fear of cancer recurrence, cancer health literacy and two measures of PE (patient activation (PA) and knowing participation in change (KPC). There was one open-ended question regarding additional survivorship concerns. Participants were recruited using Dr. Susan Love’s Army of Women Research Foundation and Craigslist. Data were analyzed via bivariate associations and backwards linear regression modeling in SPSS. Results: The final sample included 303 participants (301 females and 2 males), Μ age 50.70. The sample was predominantly White, non-Hispanic and equally dispersed across the United States. PE was significantly correlated with 13 predictors. There were 10 predictors resulting in significant ANOVA relationships with PA and KPC. In the KPC and PA regression models, HRQOL significantly predicted PE (p ≤ .001). In the KPC regression model, social support and level of education significantly predicted PE (p ≤ .001) and receipt of a survivorship care plan contributed unique variance to the model (9.1%). The open-ended question response categories included: physical and mental health concerns, financial toxicity, social support, body image concerns, other concerns or none. Conclusions: This study provides evidence that personal/demographic factors and survivorship variables may contribute to PE in breast cancer survivors. Findings may provide insight as to which survivors may be ready to engage in SC and those that may need more resources and support.
20
Muffly, Lori S., Carla Tardif, and Jonas de Souza. "Financial toxicity in children, adolescent, and young adult cancer patients and their families: A large national registry analysis from the family reach foundation." Journal of Clinical Oncology 34, no. 15_suppl (May 20, 2016): 6615. http://dx.doi.org/10.1200/jco.2016.34.15_suppl.6615.
Full text
21
Kasper, Bernd, Annie Achee, Kathrin Schuster, Roger Wilson, Gerard van Oortmerssen, Rebecca A. Gladdy, Matthew L. Hemming, et al. "Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN)." Cancers 13, no. 4 (February 20, 2021): 886. http://dx.doi.org/10.3390/cancers13040886.
Full textAbstract:
As leiomyosarcoma patients are challenged by the development of metastatic disease, effective systemic therapies are the cornerstone of outcome. However, the overall activity of the currently available conventional systemic treatments and the prognosis of patients with advanced or metastatic disease are still poor, making the treatment of this patient group challenging. Therefore, in a joint effort together with patient networks and organizations, namely Sarcoma Patients EuroNet (SPAEN), the international network of sarcoma patients organizations, and the National LeioMyoSarcoma Foundation (NLMSF) in the United States, we aim to summarize state-of-the-art treatments for leiomyosarcoma patients in order to identify knowledge gaps and current unmet needs, thereby guiding the community to design innovative clinical trials and basic research and close these research gaps. This position paper arose from a leiomyosarcoma research meeting in October 2020 hosted by the NLMSF and SPAEN.
22
Wang, Haibin, Mahendra Yatawara, Shao-Chi Huang, Kevin Dudley, Christine Szekely, Stuart Holden, and Steven Piantadosi. "The Integrated Proactive Surveillance System for Prostate Cancer." Open Medical Informatics Journal 6, no. 1 (March 2, 2012): 1–8. http://dx.doi.org/10.2174/1874431101206010001.
Full textAbstract:
In this paper, we present the design and implementation of the integrated proactive surveillance system for prostate cancer (PASS-PC). The integrated PASS-PC is a multi-institutional web-based system aimed at collecting a variety of data on prostate cancer patients in a standardized and efficient way. The integrated PASS-PC was commissioned by the Prostate Cancer Foundation (PCF) and built through the joint of efforts by a group of experts in medical oncology, genetics, pathology, nutrition, and cancer research informatics. Their main goal is facilitating the efficient and uniform collection of critical demographic, lifestyle, nutritional, dietary and clinical information to be used in developing new strategies in diagnosing, preventing and treating prostate cancer. The integrated PASS-PC is designed based on common industry standards – a three tiered architecture and a Service- Oriented Architecture (SOA). It utilizes open source software and programming languages such as HTML, PHP, CSS, JQuery, Drupal and MySQL. We also use a commercial database management system – Oracle 11g. The integrated PASS-PC project uses a “confederation model” that encourages participation of any interested center, irrespective of its size or location. The integrated PASS-PC utilizes a standardized approach to data collection and reporting, and uses extensive validation procedures to prevent entering erroneous data. The integrated PASS-PC controlled vocabulary is harmonized with the National Cancer Institute (NCI) Thesaurus. Currently, two cancer centers in the USA are participating in the integrated PASS-PC project. The final system has three main components: 1. National Prostate Surveillance Network (NPSN) website; 2. NPSN myConnect portal; 3. Proactive Surveillance System for Prostate Cancer (PASS-PC). PASS-PC is a cancer Biomedical Informatics Grid (caBIG) compatible product. The integrated PASS-PC provides a foundation for collaborative prostate cancer research. It has been built to meet the short term goal of gathering prostate cancer related data, but also with the prerequisites in place for future evolution into a cancer research informatics platform. In the future this will be vital for successful prostate cancer studies, care and treatment.
23
Alston, Shani Malia, Allison Mary Deal, Brittaney-Belle Elizabeth Gordon, Trevor Augustus Jolly, Grant Richard Williams, Samara Ann Dixon, and Hyman Bernard Muss. "Relationship of age, smoking, alcohol use, and exercise among adults with cancer." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e20582-e20582. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e20582.
Full textAbstract:
e20582 Background: Smoking, alcohol use, and exercise among cancer patients (pts) are important health concerns due to their effects on treatment outcomes. Few studies have focused on health behaviors (HB) in this group. The goal of this study was to assess HB in cancer pts seen at an academic medical center. Methods: The Health Behavior Questionnaire (HBQ) is a nine-item survey that assesses smoking, alcohol and exercise behaviors based on the 2006/7 National Health Interview Survey (http://www.cdc.gov/nchs/nhis.htm). Pts completed the HBQ from 2010 to present as part of two breast cancer (BC) trials and a geriatric assessment trial. The Jonckheere-Terpstra test compared differences among groups as age increased (Jonckheere, Biometrika 41:1/2, 1954). Results: Of 371 pts, 66% were age ≥60 (median 66), 81% white, 16% black and 95% were female. BC was most common (92%). 5% were current and 40% former smokers. 43% reported having ≥1 drinks per week (dpw). Alcohol users averaged 5 dpw (range of 1-18). 40% never exercised vigorously (≥10 minutes that causes heavy sweating or large increases in heart rate/breathing). Older pts were less likely to exercise (p <0.001). Pts who exercised vigorously were more likely to drink (p<0.02). Former smokers were more likely to use alcohol (p<0.0004). The frequency of HB by age is tabulated below. Conclusions: The % of current smokers in this sample of cancer pts was lower than the national average (5% vs 19%) as was the % of current drinkers when compared nationally (43% vs 51.5%). There was no association of age with alcohol use or smoking status. Older pts in this cohort were significantly less likely to report vigorous exercise. As exercise is important for older pts, future studies in exercise intervention would be beneficial. Support: Breast Cancer Research Foundation, New York, NY and Lineberger Comprehensive Cancer Center, Chapel Hill, NC. [Table: see text]
24
Tran, Thuan V., Huong T. T. Tran, Minh V. Hoang, Oanh T. Bui, Sang M. Nguyen, Pingping Bao, Qiuyin Cai, et al. "Establishing the Vietnam Center of Research Excellence on Cancer and Other Noncommunicable Diseases (V-CORE): Challenges and Opportunities." JCO Global Oncology 6, Supplement_1 (July 2020): 19. http://dx.doi.org/10.1200/go.20.14000.
Full textAbstract:
PURPOSE Noncommunicable diseases (NCDs), including cancer, have emerged as a major public health problem in Vietnam; however, NCD research in Vietnam is limited, primarily because of inadequate research infrastructures, funding, and well-trained investigators. To address these challenges, we established a US-Vietnam-China partnership to plan for building the V-CORE (Vietnam Center of Research Excellence on Cancer and Other Noncommunicable Diseases) with the support of a grant from the US National Cancer Institute. The objectives of this program are to assess the need and current NCD research capabilities and infrastructure in Vietnam and to develop and pilot test research capacity building/enrichment programs, including conducting two research projects for demonstration. METHODS AND RESULTS Through a need- and capacity-assessment workshop, with participation of stakeholders in NCD research and prevention in Vietnam, we identified top priorities and gaps and needs in cancer and other NCD research in Vietnam. We organized two site visits for Vietnam National Cancer Institute delegates to observe epidemiologic research field operations, core laboratories, and biorepositories at Vanderbilt University Medical Center and Vanderbilt Epidemiology Center, as well as at several partner institutes in Shanghai, People’s Republic of China. We organized an in-country workshop on the principles and methodology of epidemiology and biostatistics. We sponsored overseas training for 4 Vietnamese scholars. We conducted two demonstration projects: a case-control study involving 501 patients with breast cancer and 468 controls, and a community survey for diabetes and other metabolic conditions involving 1,035 urban and rural residents of Vietnam. We also jointly sponsored with Vietnam National Cancer Institute an international conference on cancer research and prevention in 2017, and jointly published 11 papers. CONCLUSION Within a 3-year period, we have built a productive collaborative network and laid a solid foundation for building the V-CORE in Vietnam. We strive to maintain and expand the collaboration and bring the success of the National Cancer Institute grant work to full fruition.
25
Hou, Lifang, Li Yan, Wei Zhang, Michael Yi Wang, and Shi-Yuan Cheng. "Four outstanding young Chinese scientists received the 2013 Scholar Award from the US Chinese Anti-Cancer Association and the National Foundation for Cancer Research." Chinese Journal of Cancer 32, no. 12 (December 5, 2013): 631–35. http://dx.doi.org/10.5732/cjc.013.10228.
Full text
26
Guillem, Vicente, Carlos Camps, Miguel Angel Climent Duran, Aránzazu Gonzalez del Alba, Martín Emilio Lázaro Quintela, María José Mendez Vidal, Alvaro Pinto, et al. "Expert consensus on the development of quality care measures for kidney cancer in Spain." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e19180-e19180. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19180.
Full textAbstract:
e19180 Background: To promote the continuous improvement of kidney cancer healthcare by proposing quality care measures (with respective indicators and standards) for its diagnosis, treatment and follow-up care that can be used by the corresponding professionals and that can be applied across the Spanish healthcare system. Methods: 1. a) Bibliographic review of international research (previous 5 years) on the quality of kidney cancer care; b) Multidisciplinary nominal group (9 oncology experts from the ECO Foundation –Excellence and Quality in Oncology Foundation – and 2 university methodologists – Francisco de Vitoria University Faculty of Medicine) to identify and select possible quality measures that can be applied in Spain; c) Modified Delphi Consensus (two rounds, remotely) by a panel of 55 oncologists subspecialized in kidney cancer, selected by a geographically stratified snowball sample. The ASCO (American Society of Clinical Oncology) /QOPI (Quality Oncology Practice Initiative) model is followed for the drafting of each item: definition of measures, indicators, information sources, exclusions, clarifications, categorization, acceptable standards. Results: The nominal group proposed 43 possible quality measures to the Delphi panel. Consensus participation rate = 84.5% (47 specialists). A unanimous consensus was achieved for 40 quality measures, grouped into the following areas: 4 structural, 33 regarding treatment process and 3 regarding clinical results. Conclusions: The level of consensus among Spanish oncologists subspecialized in kidney cancer on the proposed care measure for the management of said cancer is very high (93%). These results indicate widespread acceptance and applicability of said measures in the Spanish National Healthcare System and, with this in mind, they will henceforth be a valuable tool for the comparative evaluation of the quality and fairness of the oncological care of kidney cancer patients in Spain.
27
Jeon, Justin Y., Deok Hyun Jeong, Min Keun Park, Jennifer A. Ligibel, Jeffrey A. Meyerhardt, and Nam Kyu Kim. "Impact of diabetes on site-specific oncologic outcome in stage I-III colorectal cancer." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e14114-e14114. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14114.
Full textAbstract:
e14114 Background: Background: Conflicting results have been reported whether pre diagnosis diabetes mellitus (DM) influence survival of colorectal cancer patients or not. Therefore, we determine the influence of DM on long-term outcomes of stage 1-3 patients with resected colon and rectal cancer. Methods: This prospective study include a total of 4,131 participants who were treated for cancer between 1995 and 2005 in South Korea in a single hospital (Non DM: 3,614 patients, DM: 517 patients) with average follow up period of 12 years. We analyzed differences in all cause mortality, disease free survival (DFS), recurrence free survival (RFS) and colorectal cancer-specific mortality between colorectal patients with DM and those without DM. Results: After adjustment for potential confounders, pre-diagnosis DM significantly associated with increased all cause mortality (HR: 1.46, 95% CI: 1.11-1.92), and recurrence free survival reduced DFS (HR: 1.45, 95%CI: 1.15-1.84) and RFS (HR: 1.32, 95% CI: 0.98-1.76) in colon cancer patients but not in rectal cancer patients. In colon cancer patients, DM negatively affects the survival outcome of proximal colon cancer (HR: 2.08, 95%CI: 1.38-3.13), but not of distal cancer (HR:1.34, 95% CI: 0.92-1.96). Conclusions: To our knowledge, the current study first reported the effects of pre-diagnosis DM on survival outcome of colorectal cancer are site specific (proximal colon, distal colon and rectum). The current study was supported by the National Research Foundation of Korea (KRF) (No. 2011-0004892) and the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (1120230). [Table: see text]
28
Arnaldi, Ugo. "Hadrontherapy in the World and the Programmes of the Tera Foundation." Tumori Journal 84, no. 2 (March 1998): 188–99. http://dx.doi.org/10.1177/030089169808400216.
Full textAbstract:
Hadrontherapy was born in 1938, when neutron beams were used in cancer therapy, but it has become an accepted therapeutical modality only in the last five years. Fast neutrons are still in use, even if their limitations are now apparent. Charged hadron beams are more favorable, since the largest specific energy deposition occurs at the end of their range in matter. The most used hadrons are at present protons and carbon ions. Both allow a dose deposition which conforms to the tumour target. Radiobiological experiments and the results of the first clinical trials indicate that carbon ions have, on top of this macroscopic property, a different way of interacting with cells at the microscopic level. There are thus solid hopes to use carbon beams of about 4500 MeV to control tumours which are radioresistant both to X-rays and protons. After discussing these macroscopic and microscopic properties of hadrontherapy, the hospital-based facilities, running or under construction, are reviewed. The conclusion is that, while in USA and Japan twelve of these centres will be running around the year 2001, in Europe very little is foreseen to use hadrontherapy to treat deep-seated tumours. The most advanced programme is the Italian one, which is described in the last Sections of the report. The main activities concern the construction, near Milano, of a centre for protons and carbon ions called CNAO (National Centre for Oncological Hadrontherapy) and the development of new type of proton accelerators. The Istituto Superiore di Sanità in Rome obtained the initial financing for constructing, in collaboration with ENEA, a 3 GHz linac, which eventually will accelerate protons to 200 MeV, so as to allow deep protontherapy. These, and other hadrontherapy centres in Italy and Europe, will be connected with oncology centres, hospitals and clinics by a multimedial network called RITA, so that before referral each patient's case can be discussed directly by doctors, even located far away, with the experts sitting in the hadrontherapy centres.
29
Raymond, Martha Ann, and Margaret-Ann Simonetta. "Caregiver burden: Empowering caregivers with shared decision-making strategies and skills to improve patient quality of life and outcomes." Journal of Clinical Oncology 38, no. 29_suppl (October 10, 2020): 142. http://dx.doi.org/10.1200/jco.2020.38.29_suppl.142.
Full textAbstract:
142 Background: Data from the National Cancer Institute’s Surveillance, Epidemiology & End Results (SEER 2016) program estimates there are 15.5 million cancer survivors in the United States who rely on cancer caregivers every day. Caregivers play an essential role throughout the care continuum greatly impacting a patient’s quality of survivorship. Methods: August 2019–March 2020 the Raymond Foundation hosted nationwide caregiver focus groups and an online survey. Primary goals were reaching caregivers and the patients they serve in rural, urban, and community oncology settings to gain perspective from diverse populations. Focus groups were held in person and online via video conferencing. Results: 1012 caregivers and the patients they care for (41% male, 59% female) participated in our focus groups and online survey: 92% reported a lack of educational resources necessary to participate in shared decision making regarding treatment protocol; 90% reported they lacked communication strategies required to effectively communicate with their healthcare team; 87% reported they would like to learn more about clinical trials but did not know where to start; 85% reported they did not feel comfortable reporting treatment adverse effects; 94% reported working toward a patient-centered, advocate based care approach would lead to enhanced quality of life and improved outcomes. Conclusions: Cancer caregivers and the patients they assist understand the importance of shared decision-making and patient centered care. Based on our focus groups and survey findings, our call to action includes developing the Cancer Caregiver Advocacy Plan. This unique educational resource will provide key information to address educational gaps and empower caregivers to become informed healthcare advocates. The Cancer Caregiver Advocacy Plan will be a companion resource to the Raymond Foundation’s 2018 Cancer Caregiver Action Plan as we continue to expand our education and outreach to minimize cancer burdens for patients and caregivers.
30
Devenney, Kate, Niamh Murphy, Ronan Ryan, Clíona Grant, John Kennedy, Rustom P. Manecksha, Orla Sheils, Margaret L. McNeely, Juliette Hussey, and Grainne Sheill. "The feasibility of implementing an exercise programme for deconditioned cancer survivors in a national cancer centre: FIXCAS Study." HRB Open Research 2 (September 30, 2019): 24. http://dx.doi.org/10.12688/hrbopenres.12925.1.
Full textAbstract:
Introduction: As both the number of cancer survivors and the length of survival time are increasing, long-term health issues related to cancer and its treatment are becoming more prevalent. Research suggests that exercise can mitigate several negative health consequences in cancer survivors and improve physical function and quality of life. Multi-modal exercise interventions have been proposed as a cornerstone for survivorship care. However, studies evaluating exercise programmes within the Irish population are lacking. Purpose: To evaluate the introduction, implementation and acceptability of a multi-modal exercise rehabilitation programme for deconditioned cancer survivors in a real-world, standard practice setting. Methods and analysis: In this single-arm prospective feasibility study, cancer survivors (n=40) will undergo a 10-week multi-modal exercise programme. The study population will comprise of cancer survivors attending outpatient services in an Irish national cancer centre. Participants will be aged 18 or older and have completed treatment with curative intent. Feasibility will be evaluated in terms of recruitment, adherence and compliance to the programme. Secondary outcomes will examine physical function and quality of life measures. In addition, the acceptability of the programme will be assessed through patient feedback. Ethics and dissemination: Ethical approval through the St. James’s Hospital and Tallaght University Hospital Research and Ethics Committee is currently pending. The study results will be used to optimise the intervention content and may serve as the foundation for a larger definitive trial. Results will be disseminated through peer-review journals, congresses and relevant clinical groups. Trial registration: ClinicalTrials.gov NCT04026659 (19/07/19)
31
Devenney, Kate, Niamh Murphy, Ronan Ryan, Clíona Grant, John Kennedy, Rustom P. Manecksha, Orla Sheils, Margaret L. McNeely, Juliette Hussey, and Grainne Sheill. "The feasibility of implementing an exercise programme for deconditioned cancer survivors in a national cancer centre: FIXCAS Study." HRB Open Research 2 (December 18, 2020): 24. http://dx.doi.org/10.12688/hrbopenres.12925.2.
Full textAbstract:
Introduction: As both the number of cancer survivors and the length of survival time are increasing, long-term health issues related to cancer and its treatment are becoming more prevalent. Research suggests that exercise can mitigate several negative health consequences in cancer survivors and improve physical function and quality of life. Multi-modal exercise interventions have been proposed as a cornerstone for survivorship care. However, studies evaluating exercise programmes within the Irish population are lacking. Purpose: To evaluate the introduction, implementation and acceptability of a multi-modal exercise rehabilitation programme for deconditioned cancer survivors in a real-world, standard practice setting. Methods and analysis: In this single-arm prospective feasibility study, cancer survivors (n=40) will undergo a 10-week multi-modal exercise programme. The study population will comprise of cancer survivors attending outpatient services in an Irish national cancer centre. Participants will be aged 18 or older and have completed treatment with curative intent. Feasibility will be evaluated in terms of recruitment, adherence and compliance to the programme. Secondary outcomes will examine physical function and quality of life measures. In addition, the acceptability of the programme will be assessed through stakeholder feedback. Ethics and dissemination: Ethical approval through the St. James’s Hospital and Tallaght University Hospital Research and Ethics Committee is currently pending. The study results will be used to optimise the intervention content and may serve as the foundation for a larger definitive trial. Results will be disseminated through peer-review journals, congresses and relevant clinical groups. Trial registration: ClinicalTrials.gov NCT04026659 (19/07/19)
32
Zhang, Wei, Lifang Hou, Li Yan, Wei Zhang, Michael Yi Wang, and Shi-Yuan Cheng. "The US Chinese Anti-Cancer Association and the National Foundation for Cancer Research recognize five young Chinese investigators with the 2014 USCACA-NFCR Scholar Awards." Chinese Journal of Cancer 33, no. 11 (November 5, 2014): 521–26. http://dx.doi.org/10.5732/cjc.014.10221.
Full text
33
Zhang, Zetao, Yi Zhu, Zhaoping He, Yuling He, Naning Wang, and Jianping Zhao. "Hospice palliative care program management, setup, and operation with a national pilot study in Haidian, Beijing." Journal of Clinical Oncology 36, no. 34_suppl (December 1, 2018): 121. http://dx.doi.org/10.1200/jco.2018.36.34_suppl.121.
Full textAbstract:
121 Background: In 2016, an inpatient hospice palliative care ward was initiated in Beijing Haidian Hospital, which was the first pilot study program in Beijing. Challenges of implementing the program and the process to facilitate change in the hospital’s and society culture in China. Methods: This program has been partnered with Ovation Health International and Hospice Palliative Care Alliance of China Foundation at beginning of the program development in order to streamline the program design and establish standard operating procedures. The program was operated by a multi-disciplinary team which is the first of these kinds of team structure in Chinese health system, including the program manager, physicians, nurses, social workers, psychologic counsellors, chaplains, and volunteers. Results: The program has served over 200 patients and their families in the first year. The inpatient hospice unit has 2 specially decorated rooms with 6 in-patient beds, a meeting room, and a farewell room. The program has expanded its palliative care counselling service to the entire hospital and affiliated community nursing homes and will plan to expand the number of beds to 20 in the inpatient hospice unit. The implementation of the program has been full of obstacles, encompassing the lack of trained professionals, limited financial resources, higher staff turnover, and professional misunderstanding and public rejection. Now upgraded to a National Pilot model of China, the trial program team led by the program manager, has overcome core barriers/challenges in team building, team enablement, resource supporting, public education, and society awareness to keep the program growth. Conclusions: The lessons learned from the experience of developing the first hospital-based hospice palliative care program in the capital of China will be presented. Particularly, barriers and challenges, both modifiable and non-modifiable, will be shared as well as facilitating factors. The authors will share the pathway to partner across disciplines, with policy makers, and in research, education, and practice. This helps the team in the creation of new knowledge and in continuing to establish the evidence-based value of palliative care in China.
34
Kuang, Xiaying, Du Cai, Ying Lin, and Feng Gao. "Integrated immune-related gene signature to predict clinical outcome for patients with luminal B breast cancer." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e12526-e12526. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e12526.
Full textAbstract:
e12526 Background: Luminal B breast cancer is always routinely treated with chemotherapy and endocrine therapy but heterogeneous with respect to sensitivity to treatment, identification of patients who may most benefit remains a matter of controversy. Immune-related genes (IRGs) was found to be associated with the prognosis of breast cancer. The aim of this study is to evaluate the impact of IRGs in predicting the outcome of luminal B breast cancer patients. Methods: According to the Metabric microarray dataset also as a training cohort, 488 luminal B breast cancer patients were selected for generation of immune-related gene signature (IRGS). Another independent dataset (n=250) of patients with complete prognostic information was analyzed as a validation cohort. Prognostic analysis was assessed to test the predictive value of IRGS. Results: A model of prognostic IRGS containing 12 immune-related genes was developed. In both training and validation cohorts, IRGS significantly stratified luminal B breast cancer patients into immune low- and high-risk groups in terms of disease free survival (DFS, HR=4.95, 95% CI=3.22-7.62, P<0.001 in training cohort, HR=2.47, 95% CI=1.29-4.75, P<0.001 in validation cohort). Multivariate analysis revealed IRGS as an independent prognostic factor (HR=4.96, 95% CI=3.00-8.18, P<0.001 in training cohort, HR=2.56, 95% CI=1.28-5.09, P=0.007 in validation cohort). Furthermore, those 12 genes mostly related with response to chemical, and the expression levels of them were completely opposite in patients of immune low- and high-risk groups. Conclusions: The proposed IRGS is a satisfactory prognostic model for estimating DFS of luminal B breast cancer patients. Further studies are needed to assess the clinical effectiveness of this system in predicting prognosis and treatment options for luminal B breast cancer patients. This work was supported by National Natural Science Foundation of China (No. 81602520), Natural Science Foundation of Guangdong Province (No. 2017A030313596).
35
Gilbert, Julie, Matthew M. George, Elilzabeth D. Huggins, and Maureen E. Rowlands. "The Canadian True NTH Initiative: A multisite intervention to improve the lives of men with prostate cancer." Journal of Clinical Oncology 34, no. 7_suppl (March 1, 2016): 118. http://dx.doi.org/10.1200/jco.2016.34.7_suppl.118.
Full textAbstract:
118 Background: The True NTH Initiative aims to improve the lives and experiences of men with prostate cancer, as well as those of their partners, family and caregivers. In Canada, Prostate Cancer Canada selected ten teams to develop, implement and evaluate evidence-informed programs focusing on decision support, clinical support, lifestyle management, education, social support, navigation and treatment follow-up. Project teams were encouraged to align their local evaluations with a common evaluation framework and a national evaluation plan was developed. The aim of this abstract is to share methodology and early results of a multi-level evaluation that will address a range of programs designed to improve the lives of men with prostate cancer. True NTH is funded globally by the Movember Foundation, and operates in Canada, USA, UK, Australia, New Zealand, Ireland and Singapore. Methods: Projects (Solutions) selected for the initiative had existing evidence for their efficacy. Project teams were responsible for designing the implementation of their Solution and an appropriate evaluation. Local and national evaluations used a recognized framework (RE-AIM) to systematically study the real world uptake of these interventions, focusing on questions of Reach, Effectiveness, Adoption, Implementation, and Maintenance. Project teams provide quarterly narrative updates and annual written reports with quantitative measures and narrative components. Key informant interviews with project leads will complete the final national evaluation. Results: To date, projects have generated learning across different provincial health systems, academic institutions and community settings. Teams have learned to address challenges of participant recruitment and project endorsement, and have begun to appreciate the benefits of collaboration. Teams have also reflected on the importance of engaging clinicians in the implementation of their Solutions for effective uptake and sustainability. Conclusions: The results of the ongoing multi-level evaluation continue to provide insight into real world implementation of evidence-informed programs and the critical factors that enable their effectiveness.
36
Hussain, Syed Md Akram. "Comprehensive update on cancer scenario of Bangladesh." South Asian Journal of Cancer 02, no. 04 (October 2013): 279–84. http://dx.doi.org/10.4103/2278-330x.119901.
Full textAbstract:
AbstractBangladesh, at 142 million people, is the ninth most populous country in the world. There are 13 to 15 lakh cancer patients in Bangladesh, with about two lakh patients newly diagnosed with cancer each year. As an overview, lung cancer and mouth-oropharynx cancer rank as the top two prevalent cancers in males. Other types of cancers are esophagus cancer and stomach cancer. In women, cancer cervix uteri and breast cancer are most prevalent. Other cancer types, which affect women, are mouth and oropharynx cancer, lung cancer, and esophagus cancer. There are around 150 qualified clinical oncologists and 16 pediatric oncologists working in the different parts of the country. Regular cancer treatment is available in 19 hospitals and 465 hospital beds are attached as indoor or day care facilities for chemotherapy in the oncology/radiotherapy departments. There are about 15 linear accelerators, 12 Co-60 teletherapy and 12 brachytherapy units currently available. Approximately, 56 cancer chemotherapeutic agents are obtainable in Bangladesh. Research facilities are available at tertiary care centers and a few multi country collaborative research activities are ongoing. Bangladesh has a unique National Cancer Control Strategy and Plan of Action 2009-2015 formulated with the assistance of WHO with an objective to develop and implement continuum of cancer care through a comprehensive cancer control programe. Preventive measures taken to reduce the incidence of cancer include reduced tobacco smoking, change of dietary habit and reduced food adulteration, ensuring reproductive hygiene, increased physical activity, and reduced occupational hazard. Awareness buildup and media campaign are going on by organizing the general people, opinion leaders of the society, and boy and girl scout. Training of general physicians on cancer warning signs and setup of early cancer detection centers at each medical college and district levels are ongoing. Beside these, some other major cancer programs have taken place for early detection of breast, cervical and oral cancer by Bangladesh Government and NGOs such as ICDDR'B, BRAC, Ahsania Mission Cancer Hospital, BSMMU, Bangladesh Cancer Society, Ashic Foundation, Amader Gram, AK Khan Healthcare Trust, CANSUP, Oncology club etc. Piloting of cervical cancer vaccination has recently been completed. Improving the cancer scenario overnight is not an easy task but policy makers may become interested and push this agenda forward, if the huge health impact and economic loss caused by cancer become evident to them. Besides, Bangladesh has accepted reduction of cancer morbidity and mortality targets set by United Nations and World Health Organization as a part of global non-communicable disease prevention agreement.
37
Foreman, Emma, Isla Leslie, Hannah Lyons, Katherine Piddock, Anguraj Sadanandam, Alison Sanneh, Susannah Jane Stanway, Julie Webb, and Richard Cowan. "Collaborating with low- and middle-income countries: Experience from two of the United Kingdom’s comprehensive cancer centers." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e23014-e23014. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e23014.
Full textAbstract:
e23014 Background: The number of annual global cancer deaths is rising and the majority of this burden, for a multitude of reasons, falls in low- and middle- income countries (LMICs). With the United Nations’ 3rd and 17th Sustainable Development Goals in mind (which include by 2030 “reduce by one third premature mortality from non-communicable diseases” and “partnership for the goals”) a survey was undertaken at the UK’s two largest comprehensive cancer centres to scope individual and team endeavours to work with colleagues in less well-resourced countries. Methods: Employees at the Royal Marsden Foundation Trust (RM) and Institute of Cancer Research (ICR) in London and Surrey, UK and The Christie NHS Foundation Trust (Christie), Manchester were invited to complete a survey to capture collaborative clinical care, research, education and training. Results: Responses were received from 520 multidisciplinary individuals across the 2 centres to two similar questionnaires. A large number had experience of working in some capacity in, or in collaboration with an LMIC. At the RM 14.62% of respondees were currently working with colleagues in LMICs. At The Christie 13.22% of staff had experience of working in LMICs in a supportive capacity. Those currently collaborating with colleagues in LMICs were working in a wide range of countries across Asia, Africa and South America in a range of initiatives spanning clinical care, research, education and training. Of those who answered the survey 64% at The Christie said they’d like to hear more about opportunities to be involved in supporting global health care, and 89% at RM/ICR said they’d be interested in joining a collaborative group working on global oncology initiatives at the institutions. Conclusions: This survey highlights the body of willing, interested individuals keen to work with colleagues in LMICs to improve cancer outcomes. The launch of the UK Global Cancer Network in 2020 will build upon these two surveys with a planned national survey of global health and cancer work undertaken by individuals in 2021.
38
Penedo, Frank J., Betty Roggenkamp, Carol A. Rosenberg, Julia Rachel Trosman, Patricia A. Robinson, Eileen Knightly, Mary Pasquinelli, et al. "Utilization of a web-based survivorship and supportive oncology training curriculum for clinicians." Journal of Clinical Oncology 36, no. 7_suppl (March 1, 2018): 19. http://dx.doi.org/10.1200/jco.2018.36.7_suppl.19.
Full textAbstract:
19 Background: A challenge in supportive oncology, integral to patient care, is training the health professional workforce. A collaborative funded by The Coleman Foundation of 30+ clinicians (faculty) from 25 institutions (academic, community & safety net) developed a unique fundamental survivorship care (Weldon JCO 2017) and supportive oncology training curriculum (Trosman JNCCN 2017). Methods: Using data from The National Comprehensive Cancer Network Continuing Education team, we analyzed utilization of survivorship and supportive oncology education courses using simple frequencies. Results: Over 3200 courses were completed (pretest, course, post-test, evaluation) and 4850 accessed. Nurses completed 56%, physicians 15%, social workers/psychologists/support staff 14%, advance practice clinicians 8%, and various roles for the rest. Courses in table. Conclusions: NCCN’s education portal achieved strong utilization from a variety of healthcare professionals in these courses. The Coleman Supportive Oncology Collaborative supports improvement in supportive care with tools, processes and training and will continue to update/offer courses through this portal.[Table: see text]
39
Spratt, Susannah, Margaret Stewart, Samantha R. Paige, and Michael Stellefson. "A Review of the Hepatitis B Foundation Website." Health Promotion Practice 19, no. 6 (August 15, 2018): 811–14. http://dx.doi.org/10.1177/1524839918790938.
Full textAbstract:
The hepatitis B virus (HBV) is a preventable infection that can lead to chronic HBV and liver cancer without timely detection and treatment. The Hepatitis B Foundation is a national organization that helps coordinate local coalitions that work at the community level. The Hepatitis B Foundation website ( http://www.hepb.org/ ) serves as an interactive, educational website for patients, informal caregivers (e.g., family members), physicians, and community stakeholders such as local/regional health organizations and community coalitions. The multifaceted site provides user-friendly resources and tools that are available in several different languages to reach the global HBV patient population. Topic-delimited tabs (i.e., “What Is Hepatitis B?,” “Prevention & Diagnosis,” “Treatment & Management,” “Resources & Support,” “Research & Programs,” and “News & Events”) keep web content organized and easy to browse. The website also provides interactive tools such as blogs and social media campaigns that support peer-to-peer engagement. Additionally, the website stresses the importance of HBV prevention using resources on primary, secondary, and tertiary prevention. Overall, the website is a very useful tool for anyone seeking more information on topics related to HBV prevention, diagnosis, and treatment.
40
Rariy, Chevon, Lynn Truesdale, Jennifer Greenman, and Julian C. Schink. "Key features to ensure sustainability of a tele-oncology program at a national cancer center." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e13613-e13613. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e13613.
Full textAbstract:
e13613 Background: Prior to COVID-19, there were few telehealth services offered in the oncology specialty area. During the pandemic, we at a national cancer center rapidly scaled our oncology telehealth program to meet the needs of our patients. At the peak of the pandemic, telehealth initially served as a risk-mitigation strategy providing continued care to our patients while socially distancing, yet additionally, we have embedded necessary processes in place to create a sustained a telehealth oncology program that encompasses a hybrid model including face to face visits augmented with telehealth visits, where appropriate. Here we describe the key telehealth program features that have enabled a national cancer center to evolve into a hybrid model of oncology care across its five geographically distinct hospitals. Methods: Transitioning into a sustainable hybrid telehealth model of care involves a foundation of clinical leadership and partnerships among multiple departments. The telehealth oncology program leaders collaborate with the operations, technology, finance, clinical care teams, and governance council to implement telehealth growth initiatives and nimbly troubleshoot and ameliorate issues. A concierge service provides telehealth readiness checks to ensure timely resolution of issues. Workflows are followed to standardize processes. Telehealth use-cases ensure patients who need on-site services keep their in-person appointments, allowing telehealth visits for symptom management to enhance patient outcomes. A provider education session includes training on telehealth technology and “webside manner” training to ensure we preserve the personal touch with our patients in each telehealth encounter. Program data is regularly collected and reviewed to track the program’s success and opportunities for improvement. Results: After the initial peak of telehealth visits driven by the COVID pandemic, we continue to see a sustained 10-fold increase in service volume versus Jan/Feb 2020. There were 25,328 total telehealth visits from Mar. 2020-Jan. 2021, 75 clinical trial visits between July-Dec. 2020, and 848 readiness check escalations from Nov. 2020-Dec. 2021. Service lines expanded from 2 to 33, including growing rural health partnerships and a home chemotherapy infusion model. Use-cases expanded to bridge to on-site care, rapid initial visits, preop/postop checks, symptom management, and surveillance. Press Ganey patient satisfaction rates are as high as 92% and 90% of providers reported overall satisfaction with the telehealth consultations. Conclusions: Our key program features have enabled the growth and success of our enterprise tele-oncology program. One of the most promising indicators of success is the positive provider and patient satisfaction rates. Telehealth provides an effective means to provide a bridge to onsite cancer care even for our complex oncology patients.
41
Sewitch, Maida J., Mengzhu Jiang, Alan N. Barkun, David Armstrong, Donna Manca, Peter Rossos, and Barry Stein. "Report on the Expert Forum on using Information Technology to Facilitate Uptake and Impact of Colorectal Cancer Screening Guidelines." Canadian Journal of Gastroenterology 26, no. 12 (2012): 902–4. http://dx.doi.org/10.1155/2012/709627.
Full textAbstract:
The present report summarizes the proceedings of the pan-Canadian Expert Forum on Using Information Technology to Facilitate Uptake and Impact of Colorectal Cancer Screening Guidelines, which was held in Montreal, Quebec, November 18 to 19, 2011. The meeting assembled a multidisciplinary group of family physicians, gastroenterologists, nurses, patients, foundation representatives, screening program administrators and researchers to discuss the development of a mechanism or strategy that would permit the collection of comparable data by all colorectal cancer (CRC) screening programs, which would not only support the needs of each program but also provide a national perspective. The overarching theme of the meeting was ‘designing a national approach to computerized electronic data collection and dissemination for CRC screening that would improve knowledge transfer across the continuum of preventive health care’. The forum encouraged presentations on clinical, research and technical topics. The meeting fostered valuable cross-disciplinary communication and delivered the message that it is essential to develop a national health informatics approach for CRC screening data collection and dissemination to support provincial CRC screening programs.
42
Ziegler, Erik, Trinity Urban, Danny Brown, James Petts, Steve D. Pieper, Rob Lewis, Chris Hafey, and Gordon J. Harris. "Open Health Imaging Foundation Viewer: An Extensible Open-Source Framework for Building Web-Based Imaging Applications to Support Cancer Research." JCO Clinical Cancer Informatics, no. 4 (September 2020): 336–45. http://dx.doi.org/10.1200/cci.19.00131.
Full textAbstract:
PURPOSE Zero-footprint Web architecture enables imaging applications to be deployed on premise or in the cloud without requiring installation of custom software on the user’s computer. Benefits include decreased costs and information technology support requirements, as well as improved accessibility across sites. The Open Health Imaging Foundation (OHIF) Viewer is an extensible platform developed to leverage these benefits and address the demand for open-source Web-based imaging applications. The platform can be modified to support site-specific workflows and accommodate evolving research requirements. MATERIALS AND METHODS The OHIF Viewer provides basic image review functionality (eg, image manipulation and measurement) as well as advanced visualization (eg, multiplanar reformatting). It is written as a client-only, single-page Web application that can easily be embedded into third-party applications or hosted as a standalone Web site. The platform provides extension points for software developers to include custom tools and adapt the system for their workflows. It is standards compliant and relies on DICOMweb for data exchange and OpenID Connect for authentication, but it can be configured to use any data source or authentication flow. Additionally, the user interface components are provided in a standalone component library so that developers can create custom extensions. RESULTS The OHIF Viewer and its underlying components have been widely adopted and integrated into multiple clinical research platforms (e,g Precision Imaging Metrics, XNAT, LabCAS, ISB-CGC) and commercial applications (eg, Osirix). It has also been used to build custom imaging applications (eg, ProstateCancer.ai, Crowds Cure Cancer [presented as a case study]). CONCLUSION The OHIF Viewer provides a flexible framework for building applications to support imaging research. Its adoption could reduce redundancies in software development for National Cancer Institute–funded projects, including Informatics Technology for Cancer Research and the Quantitative Imaging Network.
43
Zebrack, Brad, Beth Mathews-Bradshaw, and Stuart Siegel. "Quality Cancer Care for Adolescents and Young Adults: A Position Statement." Journal of Clinical Oncology 28, no. 32 (November 10, 2010): 4862–67. http://dx.doi.org/10.1200/jco.2010.30.5417.
Full textAbstract:
Purpose This consensus-based position statement on behalf of the LIVESTRONG Young Adult Alliance (Alliance) offers recommendations to enhance oncologic care of adolescent and young adult (AYA) patients with cancer. Background In 2005 to 2006, the National Cancer Institute and the Lance Armstrong Foundation jointly sponsored the Adolescent and Young Adult Oncology Progress Review Group (PRG). The PRG report included the directive to develop standards of care for AYA patients with cancer and to disseminate these guidelines to the community. To this end, the Alliance convened a meeting of experts (clinicians, researchers, and advocates) in June 2009 and derived this position statement. Results Quality care for AYAs depends on four critical elements: timely detection; efficient processes for diagnosis, initiation of treatment, and promotion of adherence; access to health care professionals who possess knowledge specific to the biomedical and psychosocial needs of this population; and research that will ultimately derive objective criteria for the development of AYA oncology care guidelines. Achieving quality care for AYAs will require assistance with management of disease and treatment effects; cognizance of the unique psychosocial context for AYA growth and development; assessment of and attention to cognitive, psychiatric, and psychosocial issues; facilitated transition to treatment care; and referral to age-appropriate information and support services. Conclusion Dissemination of recommendations stated here will raise awareness of the need for AYA-specific care guidelines and assist providers in the delivery of care that is responsive to the distinct needs of AYAs with cancer.
44
Baldi, Antonella, and Colin Wilde. "COST Action B20: Mammary Development, Function and Cancer." Journal of Dairy Research 72, S1 (July 22, 2005): 1–4. http://dx.doi.org/10.1017/s0022029905001287.
Full textAbstract:
The COST ProgrammeThe Cooperation in Science and Technology Programme (COST) is an inter-governmental framework for European Co-operation in the field of Scientific and Technical Research. COST is managed by the European Science Foundation, and in May 2005 supported almost 200 Actions involving nearly 30000 scientists from 32 European member countries and more than 50 participating institutions from 11 non-member countries. These Actions are networks of coordinated national research project in fields which are of interest to a minimum number of participants (at least 5) from different member states. COST Actions cover basic and pre-competitive research as well as activities of public utility. The members of each Action are drawn from member countries which have ratified the Action, and their activities are informed by a programme accepted by the ESF management at time of application and reviewed on an annual basis throughout the Action. Each Action comprises three principal activities: the workshops where the science or technology matters of the Action are presented and discussed; the Action's short-term scientific missions, which allow contacts made during workshop networking to be developed; and, thirdly, the dissemination of the Action's science through publication or electronic communication.
45
Xu, Yi, Xiuli Wu, Fan Zhang, Sichu Liu, Shaohua Chen, Lijian Yang, Bo Li, and Yangqiu Li. "Overexpressed A20 in Refractory/Relapse B-ALL May Serve As a Potential Therapeutic Target." Blood 120, no. 21 (November 16, 2012): 4816. http://dx.doi.org/10.1182/blood.v120.21.4816.4816.
Full textAbstract:
Abstract Abstract 4816 Treatment failure of precursor B-lymphoblastic leukemia (B-ALL), also known as B-cell acute lymphoblastic leukemia and B-cell acute lymphocytic leukemia, remains a formidable problem. The molecular abnormalities responsible for relapse or drug resistance are still not clear. NF-κB-dependent gene expression and apoptosis plays crucial roles in numerous cellular processes, and defects in their regulation may contribute to a variety of diseases like cancers. As a key regulatory component of the cytoplasmic signaling cascade that mediates NF-κB activation in response to DNA damage, the zinc finger-containing protein A20 (also known as TNF-α-induced protein 3, TNFAIP3) has been found to correlate with drug resistance of breast cancer, prostate cancer and acute myeloid leukemia. To investigate the function of A20 in the development of B-ALL, we analyzed the expression levels of A20 and NF-κB genes in peripheral blood mononuclear cells (PBMCs) from patients (aged 3–72 years, median 30.5) with newly diagnosed B-ALL, B-ALL in complete remission (CR), and refractory/relapse B-ALL. Twenty-nine healthy individuals (aged 20–57, median 28) served as controls. We found that the expression levels of A20 in newly diagnosed B-ALL patients (23.450±16.164) and refractory/relapse B-ALL patients (26.108±12.301) were significantly higher than those from healthy controls (9.865±5.370) (P<0.0001, P<0.0001), while the expression levels of A20 in B-ALL CR patients (2.826±2.415) were significantly decreased and was lower than those from healthy controls (P=0.008). The expression levels of NF-κB in newly diagnosed B-ALL patients (2.025±0.986) were significantly higher than healthy controls (0.337±0.311) (P<0.0001), while the expression levels of NF-κB in refractory/relapse B-ALL patients (0.668±0.707) and B-ALL CR patients (0.405±0.172) were similar to healthy group (P=0.057, P=0.559). The expression levels of A20 had a positive correlation with the expression levels of NF-κB in de novo B-ALL (rs=0.7473, P=0.021), however, the expression levels of A20 in refractory/relapse B-ALL and B-ALL CR group did not show significantly correlation with the expression levels of NF-κB. In conclusion, overexpression of A20 is a feature in de novo and refractory/relapse B-ALL, which may loss their negative regulating function for NF-κB. The expression level of A20 may correlate with the clinical stages of B-ALL, indicating A20 might be considered as a prognostic marker of B-ALL and a potential therapeutic target for refractory/relapse B-ALL. Disclosures: Xu: National Natural Science Foundation of China (No. 91129720): Research Funding. Wu:National Natural Science Foundation of China (No. 91129720): Research Funding. Zhang:National Natural Science Foundation of China (No. 91129720): Research Funding. Liu:National Natural Science Foundation of China (No. 91129720): Research Funding. Chen:National Natural Science Foundation of China (No. 91129720): Research Funding. Yang:National Natural Science Foundation of China (No. 91129720): Research Funding. Li:National Natural Science Foundation of China (No. 91129720): Research Funding. Li:National Natural Science Foundation of China (No. 91129720): Research Funding.
46
Spencer, Benjamin A., Michael Steinberg, Jennifer Malin, John Adams, and Mark S. Litwin. "Quality-of-Care Indicators for Early-Stage Prostate Cancer." Journal of Clinical Oncology 21, no. 10 (May 15, 2003): 1928–36. http://dx.doi.org/10.1200/jco.2003.05.157.
Full textAbstract:
Purpose: Decisions regarding treatment for early-stage prostate cancer are frustrated not only by inadequate evidence favoring one treatment modality but also by the absence of data comparing quality among providers. In fact, the choice of provider may be as important as the choice of treatment. We undertook this study to develop an infrastructure to evaluate variations in quality of care for men with early-stage prostate cancer. Methods: We enlisted several sources to develop a list of proposed quality-of-care indicators and covariates. After an extensive structured literature review and a series of focus groups with patients and their spouses, we conducted structured interviews with national academic leaders in prostate cancer treatment. We then convened an expert panel using the RAND consensus method to discuss and rate the validity and feasibility of the proposed quality indicators and covariates. Results: The panel endorsed 49 quality-of-care indicators and 14 covariates, which make up our final list of candidate measures. Several domains of quality are represented in the selected indicators, including patient volume, pretreatment referrals, preoperative testing, interpretation of pathology specimens, and 10-year disease-free survival. Covariates include measures of case-mix, such as patient age and comorbidity. Conclusion: This study establishes a foundation on which to build quality-of-care assessment tools to evaluate the treatment of early-stage prostate cancer. The next step is to field-test the indicators for feasibility, reliability, validity, and clinical utility in a population-based sample. This work will begin to inform medical decision-making for patients and their physicians.
47
Eichmeyer, Jennifer N., Matthew Burtelow, Michael Carey, Paul Montgomery, Cynthia Graham, Dan Sayam Zuckerman, and Thomas M. Beck. "Implementing Lynch syndrome screening utilizing a community partnership." Journal of Clinical Oncology 31, no. 31_suppl (November 1, 2013): 203. http://dx.doi.org/10.1200/jco.2013.31.31_suppl.203.
Full textAbstract:
203 Background: Lynch syndrome (LS) is an autosomal dominant condition associated with an 80% risk of colorectal cancer, a 60% risk of endometrial cancer, and additional risks for extra-colonic cancers. Amsterdam and Bethesda criteria can be used to identify patients who may be at risk. However, 25% of colon cancer and 65% of endometrial cancer patients with LS will be missed by using family history criteria alone. LS is caused by mutations in mismatch repair genes (MMR): MLH1, MSH2, MSH6, PMS2, and EPCAM. Tumor screening by immunohistochemistry (IHC) is available, and abnormal results can be flagged for more definitive genetic counseling and testing. Recommendations from the 2009 EGAPP (Evaluation of Genomic Applications in Practice and Prevention) Working Group concluded there is sufficient evidence to use this tumor testing for LS, and the screening would provide moderate population benefits. Cost effectiveness studies have shown universal screening detects nearly twice as many cases of LS and is < $25,000 per life year saved. Methods: St. Luke’s Mountain States Tumor Institute (MSTI) implemented these recommendations in 2012 using a unique strategy: collaborating with a community organization. The Brian Olson Foundation (BOF) strives to “prevent(ing) colon cancer through community outreach and education and saving lives by detecting colon cancer as early as possible.”These objectives were aligned with the MSTI screening program for LS in Idaho by using BOF funding to eliminate a financial burden to the patient for 12 months. Results: 204 specimens were screened for LS using IHC with the following results: 73% normal, 21% abnormal staining for MLH1/PMS2, and 6% abnormal staining for a single protein. Three families were confirmed to have LS after molecular genetic testing, and 6 families have genetic test results pending. Conclusions: Our system had IHC numbers consistent with national data, if not slightly higher. MSTI has elected to continue the program long-term. This kind of collaboration eased the change in practice such that LS screening could become a standard of care in Idaho.
48
Price, Mark, Arliene Ravelo, Maria Sae-Hau, Peggy Ann Torney, Victor Gonzalez, Elisa S. Weiss, Carol Mansfield, et al. "Patient-reported disease burden in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma: Results from a national patient advocacy survey." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e18198-e18198. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18198.
Full textAbstract:
e18198 Background: Evaluations of patients’ (pt) burden and priorities are increasingly important as novel treatments are developed. We aimed to better understand pt-reported disease burden in chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). Methods: We developed a survey to understand pt disease burden, designed in consultation with medical experts, pt advocacy organizations, and survey scientists. Concept elicitation and cognitive pretesting were conducted. The survey was administered electronically to pts who had received either initial or subsequent treatment within the past year and consisted of categorical Likert options that quantified the impact of disease on physical function, sleep, cognition, work, emotional health, and quality of life (QoL). Results: The Leukemia & Lymphoma Society and the Lymphoma Research Foundation recruited 424 pts: 309 with CLL, 59 with DLBCL, and 69 with FL; 51% were female. Mean age was 66 (range: 22–95). Results suggest that pts experience substantial disease burden across all surveyed subtypes. The most noteworthy results are highlighted in the following table that indicates the percentage of pts who agreed or strongly agreed to statements about disease burden. Additionally, large proportions of pts worried about their disease returning or getting worse (72% of pts with CLL, 83% of pts with DLBCL, and 79% of pts with FL), indicating high impact regardless of the indolent or aggressive nature of their disease. Most pts indicated that delaying disease progression was important to them (96% of pts with CLL, 96% of pts with DLBCL, and 92% of pts with FL). Employment status changed for 31% of pts who were working full or part time or on contract because of their diagnosis and treatment. Conclusions: Pts with CLL, DLBCL, and FL report experiencing substantial disease burden. Data from studies focusing on pt-reported disease burden can be used for education of the clinical community to address the key concerns of pts.[Table: see text]
49
Alba, Patrick R., Julie Ann Lynch, Anthony Gao, Kyung Min Lee, Tori Anglin-Foote, Brian Robison, Jeremy B. Shelton, Olga Efimova, Olga V. Patterson, and Scott L. DuVall. "Using natural language processing (NLP) tools to identify veterans with metastatic prostate cancer (mPCa)." Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020): 60. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.60.
Full textAbstract:
60 Background: Veterans may benefit from promising innovations in treatments for mPCa. The Veterans Affairs (VA) and Prostate Cancer Foundation (PCF) leadership issued a challenge to identify, in real time, the national census of Veterans receiving care for mPCa. Administrative diagnostic and procedural coding do not accurately identify the risk status or disease state of prostate cancer (PCa). This study reports the development and validation of NLP tools deployed on clinical notes to identify risk status or disease state. Methods: Using diagnosis and histology codes, we queried the VA Corporate Data Warehouse to identify Veterans with prostate cancer. We included structured laboratory tests, medications, procedures, and surgeries related to prostate cancer diagnosis or treatment in the analysis. Using structured data, we identified 1000 likely mPCa cases and controls. Medical records were reviewed to confirm status and to extract term dictionaries related to cancer, anatomy, metastasis, and other diagnostic concepts. We went through several iterations of testing to refine and validate the NLP tool on a limited set of known cases and controls. We deployed the tool on all cancer, urology, pathology, and radiation oncology notes. Results: The NLP system was able to identify the patients' history of metastatic disease with 0.975 precision and 0.828 recall. Among the 1,081,137 Veterans with prostate cancer, NLP identified 63,222 (5.8%) with mPCa. There are 16,282 Veterans alive with mPCa. Mean age of diagnosis was 67 and 8,847 (54.3%) were diagnosed in the VA. Demographics were: White 9,756 (60%), Black 4,466 (27%), and other 2,060 (13%). Conclusions: NLP is a reliable tool for identifying Veterans who may benefit from novel innovations in mPCa diagnosis and treatment.[Table: see text]
50
Li, Ang, Nicole M. Kuderer, Jeremy L. Warner, Aakash Desai, Dimpy P. Shah, Julie Fu, Monica Li, et al. "Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry." Blood 136, Supplement 1 (November 5, 2020): 56–58. http://dx.doi.org/10.1182/blood-2020-138834.
Full textAbstract:
Introduction: Hospitalized patients with COVID-19 may have increased risk of venous thromboembolism (VTE) and pulmonary embolism (PE). Cancer and anti-cancer therapies are well-known additional risk factors for VTE. Nonetheless, the VTE risk in patients with both cancer and COVID-19 infection remains unknown as recent studies have not found an association due to sample size limitations. We report the incidence of and risk factors for VTE and PE among hospitalized patients with cancer and COVID-19. Methods: The COVID-19 and Cancer Consortium (CCC19) developed an international retrospective cohort study (NCT04354701) to investigate the clinical course and complications of COVID-19 among adult patients with an active or previous history of cancer. For the current study, cumulative incidences of clinically detected VTE and PE were analyzed among hospitalized patients with laboratory confirmed SARS-CoV-2. Pre-specified subgroup analysis was performed to examine the interaction between intensive care unit (ICU) admission and recent anti-cancer therapy on VTE outcomes. Bivariable logistic regression analyses were conducted to assess the association between baseline variables and VTE; unadjusted odds ratios (OR) and 95% confidence interval (CI) were reported. These variables included age, sex, obesity (BMI>30), race/ethnicity, performance status, comorbidities, blood type, history of VTE, recent surgery, recent anti-cancer therapy, cancer subtype VTE risk grouping (adapted from Khorana Score), pre-admission anticoagulant or antiplatelet use, and ICU admission status. Results: From March 17, 2020 to July 31, 2020, 3914 patients were enrolled in the CCC19 registry. For the present analysis, patients were excluded if they had inadequate follow-up <4 weeks (n=950), were not admitted to the hospital (n=1008), or had unknown VTE outcomes (n=327). Among the 1629 hospitalized patients, the median follow-up was 35 days. Patients were comprised from 3 countries (92% US, 6% Canada, 2% Spain), with a median age of 70, 45% female, and a median comorbidity score of 3. Racial/ethnic breakdown included 44% White, 26% Black, 14% Hispanic, and 13% Other. A past history of VTE was reported in 9% of patients; pre-admission anticoagulant use and antiplatelet use were reported in 25% and 35% of patients, respectively. The most common cancer types included prostate (18%), breast (15%), and lymphoma (14%). Based on the VTE risk grouping adapted from the original Khorana Score, 34% were low-risk, 29% were high-risk, and 6% were very high-risk. The receipt of anti-cancer therapy within 3 months of diagnosis was observed in 39% of patients (17% cytotoxic chemotherapy, 11% targeted therapy, 7% endocrine therapy, and 5% immunotherapy). The overall incidence of inhospital VTE and PE was 9.3% and 5.2%, respectively. The corresponding estimates were 13.4% and 7.9% among the ICU subgroup. On bivariable analysis, significant predictors of VTE included ICU admission, recent anti-cancer therapy, active cancer status, cancer subtype VTE risk grouping, and pre-admission antiplatelet use (Table 1). Pre-admission anticoagulant use had significant associations with PE but not VTE. Multivariable adjustment is ongoing to identify independent risk factor for VTE and clarify the impact of pre-admission anticoagulant/antiplatelet use controlled for other potential confounders. Both ICU admission status and anti-cancer therapy increased the risk of VTE independently. Non-ICU patients not on anti-cancer therapy had the lowest incidence of VTE (4.5%), whose estimate was similar to that reported in the non-cancer hospitalized population with COVID-19 infection. Patients with either ICU admission or recent anti-cancer therapy had the intermediate risk (11.0%), whereas ICU patients with recent anti-cancer therapy had the highest risk (16.7%). We did not observe confounding or effect modification by the ICU subgroup on the association between anti-cancer therapy and VTE. Conclusion: In this cohort study of hospitalized patients with cancer and COVID-19, recent anti-cancer therapy, active disease, high-risk VTE cancer subtypes, and ICU admission have increased risk of VTE and PE, while pre-admission anticoagulant/antiplatelet therapy may reduce the risk. This information will aid in developing a risk prediction tool for VTE in hospitalized patients with cancer and COVID-19. Disclosures Kuderer: G1 Therapeutics: Consultancy; Total Health: Consultancy; Invitae: Consultancy; Beyond Springs: Consultancy; Bristol-Myers Squibb: Consultancy; celldex: Consultancy; Bayer: Consultancy; Spectrum Pharmaceuticals: Consultancy; Janssen: Consultancy. Warner:HemOnc.orgLLC: Other: Shareholder/Stockholder/Stock options; IBM Watson Health: Consultancy; Westat: Consultancy; National Cancer Institute: Research Funding. Shah:American Cancer Society and the Hope Foundation for Cancer Research: Research Funding; National Cancer Institute: Research Funding. Zon:Amagma Therapeutics.: Consultancy, Other: stockholder. Shah:Aspen Pharma: Research Funding. Gulati:Puma Biotechnology: Consultancy; AstraZeneca: Research Funding; Isoray: Research Funding. Khaki:Merck: Other: share/stockholder; Pfizer: Other: share/stockholder. Thompson:AIM Specialty Health, BMS, GlaxoSmithKline, Takeda, Via Oncology: Membership on an entity's Board of Directors or advisory committees; Synapse Precision Medical Council: Other: Travel expenses; Doximity: Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees. Grivas:Oncogenex: Research Funding; Immunomedics: Research Funding; Debiopharm: Research Funding; Bavarian Nordic,: Research Funding; QED Therapeutics: Honoraria; Seattle Genetics: Honoraria; Roche: Honoraria; Pfizer: Honoraria, Research Funding; Mirati Therapeutics: Honoraria, Research Funding; Merck: Honoraria, Research Funding; Janssen: Honoraria; Heron Therapeutics: Honoraria; GlaxoSmithKline: Honoraria; Genzyme: Honoraria; Genentech: Honoraria, Research Funding; Foundation Medicine: Honoraria; Exelixis: Honoraria; EMD Serono: Honoraria; Driver: Honoraria; Clovis Oncology: Honoraria, Research Funding; Bristol-Myers Squibb,: Consultancy, Honoraria, Research Funding, Speakers Bureau; Biocept: Honoraria; Bayer: Honoraria, Research Funding; Astra Zeneca: Honoraria, Research Funding. de Lima Lopes:Bavarian Nordic: Research Funding; NOVARTIS: Research Funding; Tesaro: Research Funding; GSK: Research Funding; G1 Therapeutics: Research Funding; adaptimmune: Research Funding; BMS: Research Funding; Lilly: Research Funding; Merck Sharp & Dohme: Research Funding; Astra Zeneca: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Boehringer Ingelheim: Honoraria; Janssen: Research Funding; rgenix: Research Funding; Blueprint Medicines: Research Funding; Genentech: Research Funding; Roche: Research Funding; EMD Serono: Research Funding. Shyr:Roche: Consultancy; Novartis: Consultancy; Pfizer: Consultancy; Johnson & Johnson: Consultancy; GlaxoSmithKline: Consultancy; AstraZeneca: Consultancy, Speakers Bureau; Boehringer Ingelheim: Speakers Bureau; Eisai: Speakers Bureau. Pennell:Merck: Consultancy; Cota: Consultancy; Inivata: Consultancy; G1 Therapeutics: Consultancy; Astrazeneca: Consultancy; BMS: Consultancy; Eli Lilly: Consultancy; Amgen: Consultancy; Genentech: Consultancy. Friese:Eli Lilly: Consultancy; Patient-Centered Outcomes Research Institute: Membership on an entity's Board of Directors or advisory committees; Agency for Healthcare Research and Quality: Research Funding; National Cancer Institute: Research Funding; Merck Foundation: Research Funding; National Comprehensive Cancer Network: Research Funding; Pfizer: Research Funding; Eli Lilly: Consultancy. Patel:reast Cancer Research Foundation: Research Funding; Sanofi: Research Funding; Odonate Therapeutics: Research Funding; Radius: Honoraria; Genentech: Research Funding. Halmos:Foundation Medicine: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Guardant Health: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Boehringer-Ingelheim: Consultancy, Research Funding; Merck: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Eli-Lilly: Research Funding; Advaxis: Research Funding; Mirati: Research Funding; Takeda: Research Funding; GSK: Research Funding; AbbVie: Research Funding; Genentech: Consultancy; TPT: Consultancy. Choueiri:Pfizer: Consultancy, Honoraria, Research Funding; Pionyr: Consultancy, Other; Merck: Consultancy, Honoraria, Research Funding; Roche Products Limited: Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding; F. Hoffmann-La Roche: Honoraria, Research Funding; GlaxoSmithKline: Consultancy, Honoraria, Research Funding; Lilly: Consultancy, Research Funding; Peloton: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Tempest: Consultancy, Other; Lilly Ventures: Consultancy; International Patent Application No. PCT/US2018/12209, entitled "PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response," filed January 3, 2018, claiming priority to U.S. Provisional Patent Application No. 62/445,094, filed January 11, 2017: Patents & Royalties; Prometheus Labs: Consultancy, Honoraria, Research Funding; Corvus: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; Alexion: Consultancy, Honoraria, Research Funding; Bayer: Consultancy, Honoraria, Research Funding; Bristol Myers-Squibb/ER Squibb and sons LLC: Consultancy, Honoraria, Research Funding; Cerulean: Consultancy, Honoraria, Research Funding; Eisai: Consultancy, Honoraria, Research Funding; oundation Medicine Inc.: Consultancy, Honoraria, Research Funding; International Patent Application No. PCT/US2018/058430, entitled "Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy," filed October 31, 2018, claiming priority to U.S. Provisional Patent Application No. 62/581,175, filed N: Patents & Royalties; Calithera: Research Funding; Analysis Group: Research Funding; Sanofi/Aventis: Consultancy, Honoraria, Research Funding; Takeda: Research Funding; EMD Serono: Consultancy, Honoraria; Up-to-Date: Consultancy, Honoraria; NCCN: Consultancy, Honoraria; Lilly Oncology: Consultancy, Honoraria; Heron Therapeutics: Consultancy, Honoraria; Lancet Oncology: Honoraria; NEJM: Honoraria; American Society of Medical Oncology: Honoraria; Harborside Press: Honoraria; Navinata Healthcare: Honoraria; Platform Q: Honoraria; L-path, Kidney Cancer Journal, Clinical Care Options: Honoraria; Research to Practice: Honoraria; PeerView and PER: Honoraria; OnClive: Honoraria; Genentech: Consultancy, Honoraria, Research Funding; Ipsen: Consultancy, Honoraria, Research Funding; Tracon: Research Funding; Exelixis: Consultancy, Honoraria, Research Funding; Analysis Group: Consultancy, Honoraria; Michael J. Hennessy (MJH) Associates, Inc: Honoraria. Peters:Debiopharm: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding; Boehringer-Ingelheim: Consultancy, Honoraria; Blueprint Medicines: Consultancy, Honoraria; Bioinvent: Consultancy, Honoraria; Biocartis: Consultancy, Honoraria; Eli Lilly: Consultancy, Honoraria; F. Hoffmann-La Roche: Consultancy, Honoraria, Research Funding; Foundation Medicine: Consultancy, Honoraria; Illumina: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Merck Sharp and Dohme: Consultancy, Honoraria, Research Funding; Merck Serono: Consultancy, Honoraria, Research Funding; Merrimack: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Pharma Mar: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Regeneron: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Vaccibody: Consultancy, Honoraria; Biodesix: Research Funding; Daiichi Sankyo: Consultancy, Honoraria; Clovis: Consultancy, Honoraria, Research Funding; Bayer: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding. Painter:Roche: Other: stock or other ownership; OPKO Health Inc: Other: stock or other ownership; Inovio: Other: stock or other ownership; Epizyme: Other: stock or other ownership; Pfizer: Other: stock or other ownership. Rini:Astra-Zeneca: Research Funding; PTC Therapeutics: Other: Sotckholder/stock options; Surface Oncology: Consultancy; Synthorx: Consultancy; 3D Medicine: Consultancy; Arravive: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; AVEO: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Roche: Consultancy, Research Funding; Merck: Consultancy, Research Funding. Lyman:Amgen: Research Funding; Mylan: Consultancy; Beyond Spring: Consultancy; Samsung: Consultancy; Sandoz: Consultancy; Invitae: Consultancy; Spectrum: Consultancy; G1 Therapeutics: Consultancy. Connors:Bristol-Myers Squibb: Consultancy, Honoraria; Portola: Honoraria; CSL Behring: Research Funding; Takeda: Honoraria; Abbott: Consultancy, Honoraria. Rosovsky:Bristol-Myers Squibb: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Dova: Consultancy; Portola: Consultancy.